Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trialDavid Marín, Katayoun Rezvani, Ye Li et al.|Nature Medicine|2024Cited by 452
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Vikas Gupta, Uday Popat et al.|Biology of Blood and Marrow Transplantation|2015Cited by 142
Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant ResearchMichelle Long Schoettler, Sumithira Vasu, Paul A. Carpenter et al.|Transplantation and Cellular Therapy|2022Cited by 130
Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity ConditioningOlle Ringdén, Navneet S. Majhail, Ruta Brazauskas et al.|Biology of Blood and Marrow Transplantation|2014Cited by 67
<i>MECOM</i> fusion partner and bone marrow blast percentage influence outcomes of patients with <i>MECOM</i> rearranged acute myeloid leukaemiaWei‐Ying Jen, Tapan M. Kadia, Guilin Tang et al.|British Journal of Haematology|2025Cited by 3